Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
local newspaper article from lafayette, indiana
http://www.jconline.com/article/20130515/BUSINESS06/305150016/Researchers-clone-human-embryonic-stem-cells
======================
USA Today
THE RACE IS ON
With the announcement, a race of sorts starts between those who produce induced stem cells and cloned cells to see which type can most safely be grown into transplant tissues, stem cell researcher Paul Knoepfler suggests.
• Hundreds of researchers are working with induced stem cells, seeking ways to grow them into viable transplant tissues. Two clinical trials are under way that use retinal cells grown from embryonic stem cells to treat eye disease. The cells in those pilot trials are not cloned copies of the patient’s cells.
• The Food and Drug administration has stepped in to halt less-serious alterations to eggs in U.S. fertility clinics than the cloning technique reported Wednesday, says bioethicist Insoo Hyun, making it unlikely attempts at cloning a baby this way would be permitted nationwide.
An international research team has achieved a scientific first by producing embryonic stem cells from cloned embryos, advancing the effort to generate replacement tissues for sick patients.
Embryonic stems cells are the starter cells to all others in the body, which means potentially they can grow into any type of tissue, from blood to bone to brain. For a decade-and-a-half, they have been seen as a potential source of rejection-free transplant tissues for ailments ranging from diabetes to paralysis. They were also the subject of a fierce political fight during the Bush administration over the medical ethics of using human embryos in research because the embryos had to be destroyed in the process of retrieving the embryonic cells.
“We have now refined the steps to come up with a process for generating these cells that is pretty efficient,” says Shoukhrat Mitalipov of Oregon Health & Science University in Beaverton, who headed the cell cloning study released by the journal Cell. “There is no one trick to making this work. It is like winning the lottery, all the numbers have to line up the right way to win.”
Monkey tests
The study team reports a number of steps perfected in monkeys allowed the team to take eggs donated by women volunteers and successfully implant the chromosomes taken from skin cells of other people into the eggs. They successfully start the fused egg growing and dividing to become a human embryo. The cells of these embryos were as a result genetic copies, or clones, of the cells of three different people who donated the skin cells, one of them a patient afflicted with a genetic disorder called Leigh syndrome.
In a first, Mitalipov and his privately funded team report that these cloned embryos were grown past an eight-cell size (where earlier attempts had stopped) into a full-blown early embryo, containing hundreds of embryonic stem cells. Embryonic cells taken from these cloned embryos were grown into six colonies of cells, the first successfully grown cloned human embryonic stem cells. The embryos were destroyed in the cell collection process.
Some of the cells were successfully prompted to become more specialized skin and heart cells. That is the next step in someday using the cells in “regenerative” medicine, where cells cloned from a patient would be used to grow into transplant organs to treat diseases and injuries such as paralysis.
'A real milestone'
“For stem cell biology, there will be history before this result and then history after it with the study as the dividing line,” says stem cell researcher Paul Knoepfler of the University of California, Davis. “No doubt, this is a real milestone.”
Knoepfler warned that fertility clinic operators outside the U.S. might try to replicate the team’s method to try to clone a human baby.
However, Mitalipov says his team’s technique would not likely create a cloned embryo that could be implanted into a surrogate mother’s womb and lead to a pregnancy clone “The embryos we produce this way did not lead to pregnancy in monkeys,” he says. “We think there is something in the manipulations to make them that make a successful pregnancy impossible.”
This could explain TLON and why it is trading like it is. I do not understand everything in article but i am sure others will.
http://seekingalpha.com/article/794311-knight-capital-s-rescue-deal-a-lesson-for-biotech-investors
agreement reached with ALSE
Alseres Pharmaceuticals, Inc. (OTC: ALSE) today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB, "Navidea") to license, [123I]-E-IACFT Injection (CFT), also called Altropane®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease and movement disorders.
http://www.proactiveinvestors.com/columns/biomed/1825/-halozyme-confirms-complete-response-letter-for-hyq-bla-hemispherx-files-reponse-law-over-ampligen--1825.html
I do not have L2 but you can go here and get current prices:
http://www.nasdaq.com/symbol/imuc
presently:
$ 3.34 up 0.29 9.51%
May 30, 2012 14:44 ET Market Open
could this be pushing kerx up?
http://clinicaltrials.gov/ct2/show/NCT01554982?term=keryx&rank=15
ref post number 38936 - not sure if i am allowed to post about gern on this board - go read my post on gern ihub msg number 2067 board for info. I also believe the two companies news affects each other. Lynne
FDA updated several gern trials recently. http://www.clinicaltrials.gov/ct2/results?flds=Xp&flds=a&flds=b&term=geron&show_flds=Y
================
tj is to hold a press conference monday jan 30, 2012 - http://toryminus.blogspot.com/
----------------
all this looks very promising to me. sorry if someone else has posted these links, only trying to be helpful. Lynne
Peyton Manning news - channel 59 is a local indianapolis (home of the colts NFL) news station.
http://www.fox59.com/news/wxin-fox-sports-peyton-manning-had-stem-cell-therapy-20110918,0,4705898.story
Peyton Manning news - channel 59 is a local indianapolis (home of the colts NFL) news station.
http://www.fox59.com/news/wxin-fox-sports-peyton-manning-had-stem-cell-therapy-20110918,0,4705898.story
I found this article informative. There are other stocks discussed in it also.
http://seekingalpha.com/article/290960-biopharma-the-waiting-is-the-hardest-part
Finally there is Advanced Cell Technology (ACTC.OB) whose investors are anxiously awaiting some initial results from the Phase 1/2 trials dealing with human embryonic stem cell (hESC). Investors held their breath on July 14th as the company announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial cells derived from human embryonic stem cells (hESCs). The initial dosing was a relatively small (50,000 cells) and early indications are that the patients tolerated the surgical procedures well. The primary objective of these studies is to assess the safety and tolerability of these stem cells, but clinical research and animal studies suggest that even this small does might have measurable improvement in the patient’s sight.
Waiting for any word has been hard for investors as they have had to contend with the revival of a couple of old lawsuits that have resurfaced recently. Add to this a large number of outstanding shares and dwindling cash reserves and you get some nervous investors. In the end though, if ACTC can prove their science and halt macular degeneration they will stumble into a $30 billion market with relatively no competition. At that point ACTC will have enough bankroll to then pursue other more lucrative procedures using their stem cells. Until that time, the waiting will definitely be the hardest part for the shareholders of ACTC.
Clearwire Corporation (NASDAQ:CLWR):
•John W Stanton bought 1,552,182 shares at $1.78 per share for a total value of $2,762,884 on Aug 12.
•John W Stanton bought 450,000 shares at $1.88 per share for a total value of $846,000 on Aug 15.
•John W Stanton bought 477,318 shares at $1.86 per share for a total value of $889,531 on Aug 16.
http://wallstcheatsheet.com/trading/corporate-insiders-are-trading-these-shares-in-august.html/
China Integrated Energy securities are quoted under the symbol CBEH.PK on OTC Pink of the OTC Markets Group Inc. also listed on yahoo finance.
yahoo msg board has alot of info.
PR-USA.net not sure if this article has been posted but gives credibility to the company. http://pr-usa.net/index.php?option=com_content&task=view&id=756910&Itemid=29
copy of abc news broadcast. GERN nor ACT* was not mentioned. Feel free to copy this post - i have used my 3 alloted posts today. Lynne
By STEVE OSUNSAMI (@SteveOsunsami) and BEN FORER
June 2, 2011
Dr. Donald Leslie, medical director at the Shepherd Center in Atlanta, has high hopes.
"We want to cure paralysis," he said. "We want to stop spinal cord injury. How incredible would that be?"
Leslie's mission has begun with T.J. Atchinson, the first step in research that he believes could lead to many steps for those who were told they would never walk again. Atchinson, 21, was the first human with a spinal cord injury to undergo embryonic stem cell therapy.
The athletic college student's life took a hard turn in September when he was home from the University of Alabama visiting his family in Chatom and lost control of his car. Even before he was cut loose from the vehicle, he knew something was wrong.
"I realized I couldn't feel from about here down," nursing student Atchinson said, pointing to his waist. "When I got to the hospital, they said I would never walk again."
The accident took place on the birthday of Christopher Reeves, the actor who had fought hard for embryonic stem-cell therapy but never lived to receive it. Atchinson was still accepting the news about his situation when doctors told him he'd be a great candidate for the therapy.
Stem cells are the building blocks of life, and they've been used in the laboratory to repair the broken spinal cords of small animals, who walked again. Atchinson agreed to become test case No. 1.
Doctors opened his wound, while researchers used a remote control to guide the needle. They injected his spinal cord with a small dose of 2 million cells that, they hope, will transform into new nerve cells, attach to muscles and refire Atchinson's central nervous system.
Although Atchinson's role was only to prove the procedure is safe, he believes it's already working. "I can feel that," Atchinson said, pulling the hair on his legs.
After six months of the therapy, he said, he's able to sense weight when he places heavy items on his lap. It's barely there, Atchinson said, but he can sense something.
Rubbing his leg, Atchinson said, "I can feel that, there's something there."
His doctors are cautiously optimistic.
"It's very hard to measure sensation," Dr. Leslie said. "But if he tells me he couldn't feel something before, and he can now, I got to believe him. And I want this for him more than you know."
His mother, Anita McDonald, wants this, too, saying that people who oppose the therapy on religious grounds are unreasonable.
"It doesn't matter how long they've been in a chair, they all want to walk again," McDonald said. "I just know a lot of people are against it, but until they've been put in the position, I don't think they should judge anybody."
Doctors will continue to measure Atchinson's strength and test his nerves and muscles. He returns to school in the fall, moving on with his life but still holding out hope that his injury is healing.
ABC News' Harvey Goldberg contributed to this report.
==========================
there is also some other video's on this site of different pts.
======================================================================
http://abcnews.go.com/Health/spinal-cord-injury-victim-undergo-embryonic-stem-cell/story?id=13742532
here is a web site to put in browser to watch abc news (hope it works for you) http://abcnews.go.com/watch/world-news-with-diane-sawyer/SH5585921
GHLV Global Health Ventures Engages FDA Approved Contract Manufacturing Company for the Production of X-Excite
http://www.globenewswire.com/newsroom/news.html?d=223436
International Stem Cell Corp shifts management for improved effectiveness
Posted by iCELL News, on 16th May 2011, in Stem Cell Research.
International Stem Cell Corp. (OTC:ISCO) said Friday it has appointed Brian Lundstrom to focus exclusively on heading up the international partnering and therapeutic development programs for the company, a position that he was previously splitting with his duties as head of domestic operations.
The move was made in the interest of improving both domestic and international operations, the company said.
CEO, Dr. Andrey Semechkin, together with his executive team, will assume leadership of the company’s domestic operations.
“This change will increase the potential for success in the various international activities Mr. Lundstrom has initiated over the last 18 months, and I am confident the team of executives we have assembled can continue the work that needs to be done domestically without hesitation or interruption,” Semechkin said.
The international program will focus on partnerships for therapeutic development in India, China, and elsewhere outside the U.S.
International Stem Cell Corp. is focused on the therapeutic applications of human stem cells derived from parthenogenesis, the company’s core technology that avoids ethical issues surrounding stem cell research by using unfertilized human eggs.
In late April, the company successfully completed preclinical trials, transplanting liver cells, which were derived from human parthenogenetic stem cells.
http://investorstemcell.com/stem-cell-research/international-stem-cell-corp-shifts-management-for-improved-effectiveness/
I have not read anyone saying the markets opened down and closed down. I have heard everywhere i go today to play games how ppl are saying 4th day down and they have lost "tons" of money. I am fairly new to penny stocks, so my question is - does the markets have anything to do with penny stocks? ty Lynne
alot of information on the yahoo eltp msg board under title - Mr. Morris 13-May-11 05:40 pm
is this what you are looking for?
http://pr-usa.net/index.php?option=com_content&task=view&id=722175&Itemid=31
Nation's Second Participant Enrolls in Human Embryonic Stem Cell Trial
http://www.prnewswire.com/news-releases/nations-second-participant-enrolls-in-human-embryonic-stem-cell-trial-121574853.html
==============================
CHICAGO, May 10, 2011 /PRNewswire-USNewswire/ -- Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago (RIC) recently enrolled their first subject in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. This is only the second enrollment nationwide in the study sponsored by Geron Corp. (Nasdaq: GERN). Northwestern is one of five sites currently open for subject enrollment. The trial will enroll up to 10 subjects nationally.
"We are very excited to announce the second enrollment in this milestone study, which is the first to evaluate the effects of cells derived from embryonic stem cells in subjects with severe spinal cord injuries," said lead national investigator Richard Fessler, M.D., Ph.D., surgeon at Northwestern Memorial and professor of neurological surgery at the Feinberg School. "Injection of oligodendrocyte progenitor cells directly into the spinal cord lesion is a rational way to attempt to arrest or reverse the structural damage in the spinal cord caused by severe trauma."
The participant received an injection of cells over the weekend at Northwestern Memorial and will now undergo a progressive course of rehabilitation care and intervention at RIC.
"RIC's team of spinal cord injury rehabilitation specialists customize each patient's rehabilitation care plan, which may include robotic walking therapy and other procedures to facilitate the participant's neurologic repair and recovery," said David Chen, M.D., medical director of the RIC Spinal Cord Injury Rehabilitation Program. "At RIC, restoring a patient's ability is our objective and the scientific application of embryonic stem cells offers exciting new hope for recovery."
The primary objective of the Phase I trial is to assess the safety and tolerability of special cells called oligodendrocyte progenitor cells, derived from human embryonic stem cells, when they are injected into the spinal cord injury of paralyzed subjects. The injuries must have occurred within two weeks for someone to be eligible for the procedure. In addition to evaluating safety, the secondary aim of the trial is to see if the stem cells improve neuromuscular control or sensation in the trunk or lower extremities.
"The first recipient receiving the injection of oligodendrocyte progenitor cells more than six months ago has not experienced any serious adverse events attributed to the stem cell transplant to date," said Fessler. "It remains too early in the trial to determine improvement in neuromuscular control or sensation."
In previous animal studies, these stem cells have demonstrated the ability to remyelinate or recoat damaged nerve cells that have lost their ability to conduct electrical impulses down the axon. The stem cells also have shown nerve-growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury.
Subjects eligible for the Phase I trial will have documented evidence of functionally complete (ASIA Impairment Scale grade A) spinal cord injury with a neurological level of T3 to T10 spinal segments and agree to have GRNOPC1 injected into the lesion sites between 7 and 14 days after injury. For more information, go to information pages of Geron's website at www.geron.com.
http://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201103110600PR_NEWS_USPRX____CL63480&feedID=600&press_symbol=2670593
====================================================
Tuesday, May 10, 2011
Business Day
3Power Energy Enters Into $50 Million Financing Agreement
Published: March 11, 2011
NEW YORK, March 11, 2011 /PRNewswire/ -- Prime Sun Power Inc. (OTC Bulletin Board: PSPW) (Frankfurt:PSD) (the "Company"), recently rebranded as 3Power Energy Group, is pleased to announce that it has signed a financing and security agreement with CR&P Holding S.p.A., an Italian investment group, for a $50 million secured loan.
The Company intends to use the facility to finance photovoltaic, wind and hydro power plant development projects and prospective acquisitions in Italy, France Turkey, Albania and Chile. "This is a major milestone achievement for 3Power Energy and sets the Company well on the path to achieving our goal of becoming a global leader in renewable energy production" said Toby Durrant, 3Power's Chief Investment Officer. "With this initial round of financing completed, in addition to the prospective closing of the merger with Seawind, the Company will have a sound foundation for growth and the resources to pursue our key objectives" he commented.
The proceeds of this loan will principally be utilized to finance the equity portion of the first projects from the Company's existing pipeline as well as to cover some of the Company's operational expenses and predevelopment costs.
The loan is being made available to the Company at a fixed rate of 5% per annum for a period of 10 years. In addition, the lender will also receive 20% of the annual net profits derived from each project for the duration of the loan. The loan will be secured by the assets of each special purpose subsidiary holding company. Each draw of the loan amount by the Company will be subject to customary due diligence by the lender.
The agreement comes as part of CR&P and its Abu Dhabi based investment partners, to grow the group business globally within the renewable energy sector.
3Power management is coordinating with CR&P in regard to selected projects details and use of loan proceeds information in order to finalize the loan proceeds disbursement plans. "We look forward to updating our shareholders and the markets as we commence each project and capitalize on the opportunity for 3Power Energy to become a world leader in sustainable power generation," said Toby Durrant.
About CR&P Holding S.p.A.
CR&P Holding S.p.A. is a diversified investment company based in Rome, Italy, with portfolio holdings in real estate and renewable energy with recent asset valuations in excess of 323 million Euros.
About 3Power Energy Group
3POWER is emerging as a world-wide independent major player in producing sustainable renewable energy. 3POWER intends to harness cutting-edge solar, wind, and hydro technologies to develop clean, sustainable power generation as trusted energy provider to utility companies and corporate entities around the world. 3POWER expects to establish its headquarters in London, with satellite offices and operations in North America, ,Latin America, Europe, and Asia. For further information: www.3powerenergy.com.
Forward Looking Statements
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the Company, its business and prospective development plans. These forward-looking statements can be identified by the use of terminology such as "subject to," "believe," "expects," "plan," "project," "estimate," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although all of the forward-looking statements set forth in this press release are believed to be reasonable, actual results may differ materially from those expressed in forward-looking statements as a result of factors outside of the control of the Company. The Company cannot provide assurances that any prospective matters described in the press release will successfully close or otherwise be completed or that the Company will realize the anticipated benefits of any such transactions. Important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company's Securities and Exchange Commission filings. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake and specifically disclaims any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events. All forward-looking statements should be regarded solely as the Company's current plans, estimates and beliefs.
SOURCE Prime Sun Power Inc
taken from yahoo msg board- http://2012.presidential-candidates.org/Stem-Cell.php
taken from yahoo msg board - http://2012.presidential-candidates.org/Stem-Cell.php
Friday March 18, 2011 - 08:45 AM EDT
PRNewsWire News ReleasesReleased By Tycore Ventures Inc..Share:
watching this stock --------
Text Size: .SCOTTSDALE, AZ, March 18 /PRNewswire/ - Hondo Minerals Corporation (OTC:BB: HMNCD), formerly Tycore Ventures, Inc., is pleased to announce that on March 7, 2011, the Financial Industry Regulatory Authority (FINRA), approved and processed the Company's name change.
-----
Tycore Ventures started in 2007 and last date sold share price was $1.01 in dec 2010.
=======================================
you can go to the company home page and read several sec filings etc.
=====================
barchart says to hold. In order to properly form an accurate opinion, the equity or commodity has to have more than
6 months of trading activity.
price rose today 8.64% at $2.39.
==============
Moving Average Price Change Percent Change Average Volume
5-Day 2.1420 +0.3400 +16.59% 103,180
20-Day 1.9350 +0.7100 +42.26% 43,825